Long-term efficacy and safety of infliximab and cyclosporine combination therapy for refractory uveoretinitis in Behçet's disease.
Behçet’s disease
cyclosporine
efficacy
infliximab
safety
uveitis
Journal
Clinical ophthalmology (Auckland, N.Z.)
ISSN: 1177-5467
Titre abrégé: Clin Ophthalmol
Pays: New Zealand
ID NLM: 101321512
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
10
4
2019
pubmed:
10
4
2019
medline:
10
4
2019
Statut:
epublish
Résumé
This study aimed to evaluate the long-term efficacy and safety of infliximab (IFX) and cyclosporine (CsA) combination therapy for refractory uveoretinitis in Behçet's disease (BD). The study involved a retrospective review of the medical records of 11 patients with Behçet's uveoretinitis refractory to conventional treatment who had been treated with IFX+CsA combination therapy. The frequency of ocular inflammatory attacks and a Behçet's disease ocular attack score 24 (BOS24) were used as indices for the evaluation of efficacy during each 6-month period prior to and following initiation of therapy. For the assessment of safety, adverse events (AEs) were recorded throughout the treatment period. The patients had received IFX+CsA combination therapy for 5.6±2.3 years. The frequency of ocular attacks per 6-month period decreased markedly from 2.9±1.6 during the baseline period to 0.6±0.9 during months 1-6, 0.5±0.9 during months 7-12, 0.3±0.5 during months 13-18, 0.3±0.7 during months 19-24, and 0.0±0.0 thereafter ( For refractory Behçet's uveoretinitis, IFX+CsA combination therapy offers a promising treatment option as it appears to have an acceptable safety profile and can reduce the frequency and severity of ocular inflammatory attacks over a long period of time.
Identifiants
pubmed: 30962672
doi: 10.2147/OPTH.S198648
pii: opth-13-521
pmc: PMC6433110
doi:
Types de publication
Journal Article
Langues
eng
Pagination
521-527Déclaration de conflit d'intérêts
Disclosure The authors report no conflicts of interest in this work.
Références
Rheumatology (Oxford). 1999 Aug;38(8):728-33
pubmed: 10501420
N Engl J Med. 1999 Oct 21;341(17):1284-91
pubmed: 10528040
Nippon Ganka Gakkai Zasshi. 1992 Oct;96(10):1282-5
pubmed: 1442353
J Cataract Refract Surg. 2004 Feb;30(2):287-90
pubmed: 15030802
J Rheumatol. 2004 Jul;31(7):1362-8
pubmed: 15229958
Am J Ophthalmol. 2004 Sep;138(3):373-80
pubmed: 15364218
Arthritis Rheum. 2005 Aug;52(8):2478-84
pubmed: 16052571
Am J Ophthalmol. 2005 Sep;140(3):509-16
pubmed: 16196117
Int Ophthalmol. 2005 Jun;26(3):83-92
pubmed: 17031510
Clin Rheumatol. 2007 Aug;26(8):1263-7
pubmed: 17180637
Rheumatology (Oxford). 2007 Jul;46(7):1161-4
pubmed: 17478466
Jpn J Ophthalmol. 2007 May-Jun;51(3):191-6
pubmed: 17554481
Br J Ophthalmol. 2007 Dec;91(12):1579-82
pubmed: 18024808
Am J Ophthalmol. 2008 Dec;146(6):828-36
pubmed: 18708181
Graefes Arch Clin Exp Ophthalmol. 2012 Jul;250(7):1081-7
pubmed: 22234352
Ocul Immunol Inflamm. 2012 Jun;20(3):198-202
pubmed: 22486265
Arch Ophthalmol. 2012 May;130(5):592-8
pubmed: 22652845
Ocul Immunol Inflamm. 2013 Dec;21(6):468-74
pubmed: 23734940
Rheumatology (Oxford). 2014 Feb;53(2):213-22
pubmed: 23946436
Jpn J Ophthalmol. 2014 Mar;58(2):120-30
pubmed: 24482146
Ophthalmology. 2014 Oct;121(10):1877-84
pubmed: 24950593
Rheumatology (Oxford). 2014 Dec;53(12):2223-31
pubmed: 24996907
J Rheumatol. 2015 Jul;42(7):1105-11
pubmed: 26077415
Rheumatology (Oxford). 2016 Feb;55(2):210-20
pubmed: 26268816
Br J Ophthalmol. 2016 Jul;100(7):990-994
pubmed: 26553921
Clin Chem. 2016 Sep;62(9):1186-98
pubmed: 27384538
Ann Rheum Dis. 2017 Jun;76(6):1113-1136
pubmed: 28283512
Autoimmun Rev. 2017 Jun;16(6):564-575
pubmed: 28411169
Ann Rheum Dis. 2018 Oct;77(10):1539-1540
pubmed: 29453216
Rheumatol Int. 2019 Jan;39(1):47-58
pubmed: 30421105
Ryumachi. 1988 Feb;28(1):66-70
pubmed: 3388149
Ophthalmology. 1985 Apr;92(4):467-71
pubmed: 4000641